LCLaura M. Carr

Laura M. Carr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laura M. Carr has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluating the NLRP3 inflammasome in chemotherapy-induced cognitive impairment: A multi-timepoint study of methotrexate and 5-fluorouracil in female rats

    by Olivia J. Haller, Laura M. Carr, Ines Semendric, Rebecca P. George, Alexandra L. Whittaker, Lyndsey E. Collins-Praino

  • Open Access

    Towards a Biologically Defined Diagnosis: Incorporating Pathophysiological Measures Into Parkinson’s Disease Clinical Criteria

    by Angus McNamara, Laura M. Carr, Irina Baetu, Mark Jenkinson, Lyndsey Collins-Praino

    Parkinson’s disease is the second most common neurodegenerative disorder worldwide, as well as being the fastest‐growing neurological disorder. Furthermore, PD corresponds to a significant burden on those diagnosed, their caregivers and healthcare systems, highlighting the critical need for early and accurate diagnosis. Effective diagnosis is essential not only for timely intervention but also for the development of disease‐modifying treatments, which are currently unavailable for PD management. Historically, PD diagnosis and characterisation was heavily reliant on clinical presentation, which are only present after significant neurodegeneration has already occurred. Because of this, there is a consensus amongst the scientific community to transition away from clinical features and instead redefine PD diagnosis and staging based on biological presentation. This review discusses historical developments in clinical diagnostic criteria for PD as well as the role the recently developed frameworks such as SynNeurGe and the Neuronal alpha‐Synuclein Disease–Integrated Staging System (NSD‐ISS) will play in the further advancements of diagnostic practices. Furthermore, substantial research efforts into the pathobiology of PD have led to the development of novel in vivo assessments capable of detecting critical biomarkers of PD. Specialised imaging modalities, particularly nuclear imaging and magnetic resonance imaging, and biomarkers of α‐synuclein pathology demonstrate high sensitivity and specificity for not only early diagnosis but also differential diagnosis between other parkinsonisms. Beyond diagnostic reforms, it is also important to identify markers that could serve as indicators of clinical course to aid in tailoring personalised treatment strategies. Therefore, this review also summarises key pathobiological hallmarks of PD beyond α‐synuclein pathology, namely, dopaminergic denervation, copathologies and underlying indicators of neurodegeneration, such as iron deposition and neuroinflammation. Furthermore, strategies to assess such pathologies and their potential utility in the current paradigm shift towards biological characterisation are discussed.


  • Open Access

    Comparison of automated and manual approaches for microglial quantification and classification: A focus on the HALO digital pathology platform

    by Laura M. Carr, Bianca Guglietti, Ing Chee Wee, Ian F. Musgrave, Sanam Mustafa, Frances Corrigan, Lyndsey E. Collins‐Praino

    Phenotypic changes in microglia have been linked to multiple neurological conditions, such as dementia, Parkinson's disease, stroke and traumatic brain injury. Consistent identification and classification of microglia is essential in understanding potential links with neurological diseases. Currently, there are several ways by which the microglial population and morphology are assessed, including manually or using open‐source image analysis platforms, such as ImageJ . A microglial classification module for the HALO digital pathology platform has been developed for this purpose but has not yet been validated within the literature. The current study therefore conducted a comparison of the performance of this HALO module to manual microglial analysis and to automated analysis via ImageJ using both human and rat brain tissue. In 5 μm thick human tissue, total and activated microglia/mm 2 counted by HALO showed strong positive correlations with both manual and ImageJ counts. HALO did not differ from the other methods for total microglia counts; however, Halo did differ from both manual and ImageJ methods in the number of activated microglia detected within the substantia nigra. In 20 μm rat tissue, total counts derived from HALO showed moderate positive correlations with both manual and ImageJ counting; however, activated counts on Halo were not positively correlated with any method. To our knowledge, this is the first study to systematically compare the Halo module to other common methods of microglia analysis. When applied to 5 μm tissue, the Halo module is comparable to manual counting and to automated analysis on ImageJ . However, when analyzing thicker tissue, Halo struggles to perform in line with these other methods, particularly for counts of activated microglia, likely due to increased cell density and the morphological complexity of microglia. These results highlight the importance of carefully tailoring image analysis parameters on automated counting methods to suit the needs of the tissue.

  • Open Access

    Application of diceCT to Study the Development of the Zika Virus-Infected Mouse Brain

    by Amy L. Green, Evangeline C. Cowell, Laura M. Carr, Kim Hemsley, Emma Sherratt, Lyndsey E. Collins-Praino, Jillian M. Carr

    Zika virus (ZIKV) impacts the developing brain. Here, a technique was applied to define, in 3D, developmental changes in the brains of ZIKV-infected mice. Postnatal day 1 mice were uninfected or ZIKV-infected, then analysed by iodine staining and micro-CT scanning (diffusible iodine contrast-enhanced micro-CT; diceCT) at 3-, 6-, and 10-days post-infection (dpi). Multiple brain regions were visualised using diceCT: the olfactory bulb, cerebrum, hippocampus, midbrain, interbrain, and cerebellum, along with the lens and retina of the eye. Brain regions were computationally segmented and quantitated, with increased brain volumes and developmental time in uninfected mice. Conversely, in ZIKV-infected mice, no quantitative differences were seen at 3 or 6 dpi when there were no clinical signs, but qualitatively, diverse visual defects were identified at 6–10 dpi. By 10 dpi, ZIKV-infected mice had significantly lower body weight and reduced volume of brain regions compared to 10 dpi-uninfected or 6 dpi ZIKV-infected mice. Nissl and immunofluorescent Iba1 staining on post-diceCT tissue were successful, but RNA extraction was not. Thus, diceCT shows utility for detecting both 3D qualitative and quantitative changes in the developing brain of ZIKV-infected mice, with the benefit, post-diceCT, of retaining the ability to apply traditional histology and immunofluorescent analysis to tissue.


  • Open Access

    Application of diceCT to Study the Development of the Zika Virus Infected Mouse Brain

    by Amy L Green, Evangeline C Cowell, Laura M Carr, Kim Hemsley, Emma Sherratt, Lyndsey Collins-Praino, Jillian M Carr

    Zika virus (ZIKV) impacts the developing brain. Here a technique was applied to define, in 3D, developmental changes in the brain of ZIKV-infected mice. Postnatal day 1 mice were uninfected or ZIKV-infected, then analysed by iodine staining and micro-CT scanning (diffusible iodine contrast enhanced micro-CT; diceCT) at 3-, 6- and 10-days post infection (dpi). Multiple brain regions were visualised using diceCT; olfactory bulb, cerebrum, hippocampus, midbrain, interbrain, and cerebellum, along with the lens and retina of the eye. Brain regions were computationally segmented and quantitated, with increased brain volumes with developmental time in uninfected mice. Conversely, in ZIKV-infected mice, no quantitative differences were seen at 3 or 6 dpi, when there are no clinical signs, but qualitatively, diverse visual defects were identified at 6-10 dpi. By 10 dpi, ZIKV-infected mice had significantly lower body weight and reduced volume of brain regions compared to 10 dpi-uninfected or 6dpi ZIKV-infected mice. Nissl and immunofluorescent Iba1 staining on post-diceCT tissue were successful, but RNA extraction was not. Thus, diceCT shows utility for detecting both 3D qualitative and quantitative changes in the developing brain of ZIKV-infected mice, with the benefit, post-diceCT, of retaining the ability to apply traditional histology and immunofluorescent analysis to tissue.

  • Open Access

    Fyn kinase inhibition using AZD0530 improves recognition memory and reduces depressive-like behaviour in an experimental model of Parkinson’s disease

    by Bianca Guglietti, Laura Carr, Benjamin Ellul, Sanam Mustafa, Frances Corrigan, Lyndsey E Collins-Praino

    Fyn kinase has recently been established as a major upstream regulator of neuroinflammation in PD. This study aimed to determine if inhibition of Fyn kinase could lead to reduced neuroinflammation and improvements in motor and non-motor impairments in an early-stage model of PD. An experimental model of PD was produced using intra-striatal injection (4µl) of the neurotoxin 6-OHDA (5µg/µl). Sprague Dawley rats (n=42) were given either vehicle, 6mg/kg or 12mg/kg of Fyn kinase inhibitor (AZD0530) daily for 32 days via oral gavage and tested on a battery of tasks assessing motor, cognitive and neuropsychiatric outcomes. AZD 0530 administration led to improvement in volitional locomotion and recognition memory, as well as a reduction in depressive-like behaviour. Pathologically, an inflammatory response was observed; however, there were no significant differences in markers of neuroinflammation between treatment groups. Taken together, results indicate a potential therapeutic benefit for use of Fyn kinase inhibition to treat non-motor symptoms of PD, although mechanisms remain to be elucidated. HIGHLIGHTS: Fyn kinase has recently been proposed as a major upstream regulator of microglial activation in Parkinson’s disease (PD). This study was the first to evaluate the effects of Fyn kinase inhibition in a rodent model of PD. Fyn kinase inhibition using the Fyn kinase inhibitor AZD 0530 was capable of improving volitional locomotion and recognition memory and reducing depressive-like behaviour in a rodent model of PD. Interestingly, while increases in microglial activation were observed in this rodent model of PD, AZD 0530 did not significantly reduce this activation. This suggests that the behavioural improvements associated with Fyn kinase inhibition may occur independently of neuroinflammation and may be attributable to other brain mechanisms, including actions on NMDA or 5-HT 6 receptors.